Molecular profiling of primary lung cancer and its metastatic site

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects matched tissue samples from primary non-small cell lung tumors and their metastatic sites and performs tumor DNA next-generation sequencing. The plan is to compare genomic and molecular differences between the two locations to characterize divergence and potential actionable targets. Eligible participants are adults who can safely undergo the planned surgical procedure and can provide sufficient tumor tissue for sequencing. Standard exclusions include pregnancy or breastfeeding, significant active infections, or other medical contraindications to participation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients aged ≥18 years fit enough to tolerate the surgical operation;
* the operative risk is considered low based on respiratory reserve and cardiac assessment;
* the patient has clearly expressed willingness to adhere;
* availability of pathological material for tumor DNA extraction and NGS execution.

Exclusion Criteria:

* Women of childbearing age, pregnant or breastfeeding, or intending to become pregnant during the study.
* Any other illness, metabolic disorder, physical examination, or laboratory findings that constitute a contraindication to study participation.
* Recent or ongoing severe or clinically significant infection.

Where it's running

• Istituto Europeo di Oncologia
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Lorenzo Spaggiari — European Institute of Oncology
• Study coordinator: Luca Bertolaccini
• Email: luca.bertolaccini@ieo.it
• Phone: +390257489244

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Boosting lung cancer screening for patients seen in the emergency department

  This project will test whether giving eligible emergency department patients a facilitated referral plus text reminders helps more people get lung cancer screening.

  Recruiting University of Rochester · Rochester, New York · NCT07287085

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Risk-based lung cancer screening in COPD patients using ML and clinical models

  This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.

  Recruiting Vejle Hospital · Vejle, Region Syddanmark · NCT07848815

• AI-Personalized Discharge Education After Lung Cancer Surgery

  This study tests whether an AI-generated, personalized discharge guide helps patients recover better after lung cancer surgery compared with standard discharge education.

  Recruiting Xiamen University · Siping, Jilin · NCT07827183

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.